washingtonpost.com  > Technology > Washtech > Companies > Start-up


Monday, February 14, 2005; Page E05

Name: PharmAthene Inc.

Location: Annapolis

Big idea: Developing countermeasures for bioterrorism, including treatments and vaccines for anthrax and other chemical toxins.

_____Start-up Archive_____
PharmAthene Battles Anthrax (The Washington Post, Feb 14, 2005)
In Profile (The Washington Post, Feb 7, 2005)
Using Net to Reach Developing Countries (The Washington Post, Feb 7, 2005)
Paxfire, Inc. (The Washington Post, Jan 31, 2005)

Founded: 2001

Web site: www.pharmathene.com

Who's in charge: David P. Wright, president and chief executive

Funding: PharmAthene received $13 million in seed money from the Defense Advanced Research Projects Agency (DARPA), raised $15 million in a first round from HealthCare Ventures, and raised $50 million in a second round from MPM Capital, Bear Stearns Health Innoventures and HealthCare Ventures.

Employees: 15. The company will add 56 employees when it completes its acquisition of Nexia Biotechnologies Inc.

Partners: PharmAthene is collaborating with Medarex Inc. to develop a monoclonal antibody called Valortim. The company has a relationships with DARPA, the Army Medical Research Institute of Infectious Disease, the University of Wisconsin's Alumni Research Foundation and the Salk Institute in San Diego. The company is also in a research collaboration partnership with the University of Maryland.

Origin of company name: "Athena is the goddess of warfare and the protectorate, so it's pharmaceutical protection against warfare," Wright said.

© 2005 The Washington Post Company